Mutator phenotype tumors provide unique opportunities to unravel malignant progression because of various gene alterations acquired during clonal tumor evolution. Gastric carcinomas, which have been known to show frequent genetic instability, would be composed of initial gene alterations shared by most tumor areas and subsequent alterations restricted to particular tumor sites. To analyse the timing of genetic events, we examined separate sites of tumor tissue obtained from a given gastric carcinoma patient with microsatellite instability (MSI). Our study included 95 normal/tumor area pairs from 25 patients. Six of the 25 patients (24%) demonstrated various levels of MSI ranging from 7% (two of 30) to 97% (28 of 29) of markers tested in multiple tumor sites. Of the six patients, ®ve manifested frameshift mutations in a tract of ten deoxyadenosines within transforming growth factor b receptor type II and four demonstrated frameshift mutations in a tract of eight deoxyguanosines within BAX. These mutations were common to all tumor sites regardless of the various level of MSI phenotype, indicating initial events. Two of the six patients exhibited frameshift mutations in mononucleotide repeats of mismatch repair genes, hMSH3 and hMSH6, and the insulin-like growth factor II receptor in restricted tumor areas, indicating additional alterations. Insulin-like growth factor II receptor mutations appear to be caused by hMSH3 and hMSH6 mutations because the former mutations were con®ned to tumor portions with the latter two mismatch repair lesions. These results provide genetic progression evidence for gastric carcinomas of the mutator pathway. In this pathway, mismatch repair insuciency initially targets mononucleotide tracts of transforming growth factor b receptor type II and BAX. During tumorigenesis, primary mismatch repair failure may give rise to the secondary mismatch repair lesions, frameshift mutations of hMSH3 and hMSH6, which result in another tumorigenic mutation in the insulin-like growth factor II receptor.
Introduction
Cancer is a stepwise progressive disease requiring several mutations, and a precise genetic model of tumor progression has been proposed based on a mutator phenotype (reviewed in Loeb, 1991) . Genetically unstable tumors arising in patients with hereditary nonpolyposis colorectal cancer exhibit a mutator phenotype characterized by frequent somatic mutations in their simple repeat sequences, so called microsatellite instability' (MSI; Aaltonen et al., 1993; Thibodeau et al., 1993; Ionov et al., 1993) . Two major human homologues of bacterial and yeast genes encoding proteins required for DNA mismatch repair (MMR), hMSH2 (Aaltonen et al., 1993; Fishel et al., 1993) and hMLH1 (Lindblom et al., 1993) , were identi®ed from the linkage studies on hereditary nonpolyposis colorectal cancer kindreds. Subsequently, germ-line mutations of these MMR genes were found in aected individuals (Leach et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994) , and MSI is considered a mutator phenotype caused by MMR failure. Sporadic and familial gastric cancers have also been known to be frequently associated with the genetically unstable phenotype (Thibodeau et al., 1993; Han et al., 1993; Rhyu et al., 1994; Akiyama et al., 1996) . However, most evidence supporting the importance of a mutator phenotype in gastrointestinal carcinogenesis has been thus far derived from noncoding microsatellite sequences throughout the genome of mutator phenotype tumors.
Recent studies found that the genetic instability of gastrointestinal cancers targeted the polyadenylate short tract within the coding region of transforming growth factor b receptor type II (TGF-b RII) gene, generating nonsense codons downstream Myero et al., 1995; Parsons et al., 1995b) . The mutations result in liberating gastrointestinal epithelial cells from the growth constraint of transforming growth factor b leading to uncontrolled cell growth. Likewise, MSI-associated frameshift mutations have been frequently detected in tracts containing repetitive mononucleotide of the coding regions of cancer-related genes other than TGF-b RII gene, such as the insulin-like growth factor II receptor (IGFIIR; Souza et al., 1996) and BAX (Rampino et al., 1997) . Functionally, the IGFIIR downregulates the proliferation of cells by internalization and subsequent degradation of its ligand (Oka et al., 1985) , insulinlike growth factor II, which plays a crucial role in the maintenance of the transformed phenotype and protects cells from apoptosis . Furthermore, BAX promotes apoptosis in opposition to Bcl-2 that suppresses apoptosis (Oltvai et al., 1993) . It is therefore likely that sequential steps from MMR failure to genetic instability and somatic mutations within the coding regions of cancer-related genes confer cellular immortality and/or proliferation.
On the other hand, the animal models of MMR de®cient mice revealed interesting evidence that only malignant tissue is susceptible to the instability phenotype. For example, lymphoid tumor that was produced in Msh27/7 mice contained MSI, while adjacent normal tissues as well as any somatic tissues of the mice could not easily demonstrate the genetic instability (Reitmair et al., 1995) . Moreover, in Apc+/7/Msh27/7 mice that accelerated APCmediated intestinal tumorigenesis, the increased number of colon and small bowel adenomas showed no alterations within microsatellite markers (Reitmair et al., 1996) . The presence of the instability phenotype restricted to malignant tumor tissue implicates that alterations of the coding regions are necessary for conferring the selective pressure to the mutator phenotype in addition to MMR defect. Considering the mutator phenotype in the stepwise tumorigenic pathway, the phenotype itself would be demonstrated after MMR insuciency combined with selective growth advantage.
The ®rst gene alteration conferring immortality or growth advantage would be shared by most tumor cells. Conversely, gene alterations acquired during clonal tumor evolution would be restricted to particular tumor areas. To analyse the timing of MSI and frameshift mutations in the coding DNA portions, we examined several distinct areas of tumor tissue obtained from a given patient who had gastric carcinoma with MSI. Of MSI-associated frameshift mutations in this study, mutations of TGFb RII and BAX genes were shared by all tumor areas examined. As expected, the mutator phenotype seems to have been acquired additionally during clonal expansion driven by the mutations of the coding regions of these two genes. Mononucleotide repeats of the IGFIIR as well as two MMR genes, hMSH3 and hMSH6 both of which are already known to be targeted in mutator phenotype cancers (Malkhosyan et al., 1996) , were screened for the frameshift mutation to unravel their role in multistep tumor progression.
Results

Analysis of microsatellite instability in various tumor areas
Depending on tumor size and the presence of available paran-embedded tissue, two to seven separate tumor areas (i.e., at positions 12, 3, 6 and 9 o'clock of tumor) were individually selected from each patient with gastric carcinoma. A total of 95 normal/tumor area pairs obtained from 25 patients were examined using 31 microsatellite markers. Six of the 25 patients (24%) demonstrated widespread MSI shared in either particular tumor sites or most tumor areas examined. Histological ®ndings of individual sites are listed in Table 1 . Individual tumor areas of a given patient demonstrated various mutation frequencies in microsatellite sequences (Table 2 ). In the cases of patients 68 and 69, for instance, individual areas demonstrated dierent levels of MSI with a wide range from 19% (six of 31) to 87% (27 of 31) and from 7% (two of 30) to 80% (24 of 30) of markers tested, respectively. As the genetically advanced areas displayed more mutant alleles, we were able to order mutator phenotype progression according to the levels of MSI. The patterns of MSI (altered length of novel alleles) were dierent among individual tumor areas and the markers. Representative examples of diverse-sized microsatellite alleles are shown in Figure 1a and d. These heterogenous patterns of MSI implicate that genetically unstable tumor cells have dierent mutation rates or growth rates. Some particular tumor sites with low-level MSI are considered to be in the initial stage of the development of widespread MSI, which are derived from a common single progenitor clone harboring a mutator genotype or MMR de®ciency. However, patient 57 demonstrated two dierent histological types, the intestinal type in MSI-positive area (T2, 3, 4 and 5) and the diuse type in MSInegative area (T1), indicating clonal outgrowth of a subpopulation of cells with an additional mutator phenotype.
Frameshift mutations within the mononucleotide tracts of cancer-related genes
Multiple sites of tumor tissues of the six patients were also screened for the presence of frameshift mutations in repetitive mononucleotide tracts of cancer-related genes, such as TGF-b RII, BAX, IGFIIR, hMSH3 and hMSH6. The results of MSI-related mononucleotide tract mutations of the six patients are listed in Table 2 . Five (83%) and four (67%) of the six gastric carcinomas with MSI manifested frameshift mutations in the poly (A) 10 tract of TGF-b RII and the poly(G) 8 tract of BAX, respectively. Thus, all the six gastric carcinomas accompanied frameshift mutations of TFGb RII and/or BAX genes, including three cases (50%) with mutations in both genes (Table 2) . Remarkably, the mutations of these two genes were observed commonly in all tumor sites regardless of various MSI levels (Table 2, Figure 1b , Figure 2a ). Even the individual tumor sites of patients 67 and 68 who showed a wide range of MSI level had both TGF-b RII and BAX, or TGF-b RII mutations in all tumor areas tested, respectively (Table 2 ). These two genes therefore seem to have mutated early and speci®cally in the development of mutator phenotype cancer. Consistently, patient 57 showed TGF-b RII mutations con®ned within MSI-positive sites, T2 to 5, but no mutations in MSI-negative site, T1 (Figure 1e ). Frameshift mutations within the tracts of two MMR genes, hMSH3(A) 8 and hMSH6(C) 8 , were observed in restricted tumor areas of three (50%) of the six patients, indicating secondary MMR gene alterations caused by primary MMR insuciency (Table 2, Figure  1e ). Interestingly, frameshift mutations within IGFIIR(G) 8 were localized corresponding to the presence of hMSH3 and hMSH6 mutations in T4 and 5 sites of patient 57 (Figure 1e ), and localized in T4 and 5 of patient 95 showing hMSH3 mutations common to all tumor site (Figure 1b ), but not observed in any tumor sites of the other four patients ( Table 2) . The IGFIIR gene is likely aected due to the secondary MMR defects.
Allelic loss and mutation of p53 gene
Using microsatellite markers, interpretation of allelic loss parallel with MSI is dicult since it cannot be certain if the apparent`loss' of one allele represents a true loss or mutation to the germline allele (i.e., allele shifting by altered molecular weight). As seen in Figure  1a and d, it is not clear if novel-sized alleles on electrophoretic gel accompany LOH in TP53 locus or not. To con®rm the presence of LOH, we used two restriction fragment length polymorphic markers and one variable number of tandem repeat marker intragenic to p53 independent of MSI. LOH at p53 locus were observed in all tumour areas of patients 57 and 95 regardless of the heterogenous patterns of MSI (Figure 1c . The other three cases, 67, 68 and 69, were not informative for LOH study at the three intragenic markers. These ®ndings indicate that p53 gene alteration might precede a mutator phenotype, if occurring in the development of gastric carcinoma with a mutator phenotype.
Discussion
Ordering the genetic events in genetically unstable tumors, which suer various gene alterations during clonal tumor evolution, provide unique opportunities to unravel the malignant progression. Basically, genetic abnormalities which play a role for selective cell growth advantage early in carcinogenesis, are common to most tumor areas. In contrast, late-onset abnormalities are restricted to particular areas of tumor tissue. By investigating various separate areas of a gastric tumor tissue with MSI, we described a general order of genetic progression for mutator phenotype cancers in which frameshift mutations occur commonly in the repetitive mononucleotide tracts of cancer-related genes. Gastric carcinoma with MSI would be closely related to intestinal metaplastic regions in the stomach, because TGF-b RII frameshift mutations cause neoplastic outgrowth of intestinal epithelial cells only . In fact, MSI occurs more frequently in intestinal-type gastric carcinoma than the diuse type (Chung et al., 1996) . Except in two cases showing no TGF-b RII mutations, the MSInegative tumor site of patient 57 and all sites of patient 72 with p53 mutation, most gastric carcinomas in this study histologically exhibited the intestinal type (Table  1 ). This close relationship between MSI and gastric carcinomas shows that intestinal metaplasia provides phenotypic premalignant lesion susceptible to TGF-b RII mutation during gastric tumor progression. Nevertheless, few MSI has been shown even in the precancerous stages such as gastric dysplasia or metaplasia in human (Rhyu et al., 1994) as well as small bowel adenomas generated in Msh2-de®cient mice (Reitmair et al., 1996) . Since MMR insuciency itself cannot produce a growth advantage for a clonal population, a mutator phenotype seems to need cellular immortality for accumulation of mutations detectable in tissue. We therefore chose arbitrarily several areas smaller than 5 mm in diameter to obtain genotypically homogenous clones within a carcinoma tissue.
Recent studies support that the outgrowth of gastrointestinal tumor cells with MSI is driven by the mutations of TGF-b RII or BAX genes Myero et al., 1995; Parsons et al., 1995b Rampino et al., 1997 (Souza et al., 1996; Malkhosyan et al., 1996) , MSI-associated frameshift mutations were less frequently present within the tracts of IGFIIR, hMSH3, and hMSH6 than TGF-b (Table 2) . These three patients demonstrated widespread MSI common to all tumor areas tested, whereas frameshift mutations of the three genes were localized in particular sites. It is plausible that the mutations of IGFIIR, hMSH3 and hMSH6 genes arise additionally to the mutator phenotype during tumor progression. Especially, the presence of IGFIIR mutations were con®ned within the sites with both hMSH3 and hMSH6 or hMSH3 mutations (Figure 1b and e), indicating that MMR insuciency causes secondary MMR lesions resulting in additional frameshift mutation of another tumor suppression gene. This malignant cascade of a mutator phenotype explains the reason why tumor progresses to a more malignant phenotype as it develops. Regarding p53 gene alteration underlying MSI, sporadic gastric carcinomas accompanied frequent p53 allelic loss (eight of 11, 73%; Chong et al., 1994) in contrast to infrequent allelic loss in the initial studies of colon cancers (one of eight, 13%; Thibodeau et al., 1993) . In the present study, three of the six (50%) gastric carcinomas with MSI demonstrated p53 gene alterations including three allelic losses and one missense mutation. Gastric carcinomas of a mutator phenotype therefore appear to arise in a distinct manner from hereditary colorectal cancers in which defective MMR genes lead to subsequent oncogenic gene lesions. During gastric carcinogenesis, p53 alteration is known to be associated with progression from intestinal metaplasia to dysplasia (Correa and Shiao, 1994) . Assuming that malignant tumor expansion with a mutator phenotype is driven by the mutations of TGF-b RII or BAX genes, our results suggest that the frameshift mutations result from newly acquired mutaor genotype, which has yet been unidenti®ed in gastric carcinoma, subsequent to p53 alteration occurring in dysplastic region of the stomach. The recent study of Bax-de®cient mice (Yin et al., 1997 ) demonstrated p53-dependent expression of Bax as a component of p53-mediated apoptosis. Moreover, inactivation of one allele of Bax or p53 genes eectively accelerated tumor growth rate as a result of reduced apoptosis. MSI-associated BAX frameshift mutations involving one allele therefore appear to contribute to gastric tumor progression in association with loss of the p53 allele. These ®ndings support that p53 LOH and BAX mutations detected in this study are selective in the cancer tissues with MSI.
There have been several in vitro studies that are helpful in understanding p53 role in sporadic cancers of a mutator phenotype. Tumor cells that were resistant to alkylating agents acquired a mutator phenotype (Branch et al., 1993; Kat et al., 1993) . Because MMR protein serves as a sensor for the DNA damage caused by these agents (Karran and Stephenson, 1990) , loss of MMR function is thought to result in a failure to generate the apoptotic signal. In the present study, patient 72 with MSI, who has p53 missense mutation as well as BAX frameshift mutation, is likely the case that the coincidence of these genetic lesions in relation to apoptosis exerts an immortalizing eect on tumor cells with a mutator phenotype. The frequent presence of TGF-b RII mutations in mutator phenotype cancers simply re¯ects that MMR insufficiency targets preferntially the mononucleotide tract of the coding regions which play a role in tumor outgrowth.
The recent studies of various cancers other than gastrointestinal tumors have introduced the alternative pattern of MSI in association with LOH (Merlo et al., 1994; EyfjoÈ rd et al., 1995; Fong et al., 1996; Larson et al., 1996; Zhu et al., 1996) . This instability phenotype seems to be dierent from that of a subset of gastrointestinal cancers because of its infrequent incidence and lowlevel (or non-widespread) patterns involving a few N  T1  T2  T2   N  T1  T2  T3   TP53 BAX ( In conclusion, we described the multistep tumor progression of a mutator phenotype from MMR insuciency to frameshift mutations of two cancerrelated genes TGF-b RII, BAX, and to the second genetic lesions in two MMR genes, hMSH3 and hMSH6, followed by another tumorigenic mutations in the IGFIIR. This malignant phenotype progression could be expected of tumors in which cancer genes are stepwise inactivated by other mechanisms than MMR insuciency. Our ®ndings highlight the postulate for the molecular origin of gastric carcinogenesis in detail.
Materials and methods
Tissue samples
Ethanol-®xed, paran-embedded tissues were obtained from surgically treated gastric carcinoma patients in St Paul's Hospital, Catholic University Medical College, Seoul, Korea. Twenty-®ve patients were randomly selected for this study, consisting of 18 men and seven women from 31 to 77 years of age at the time of surgery. All tumors were examined by the pathologist and classi®ed according to the criteria of the World Health Organization (Oota and Sobin, 1977) . Two to seven separate tumor areas smaller than 5 mm in diameter were individually microdissected for each case. Ninety-®ve normal/tumor area pairs were examined in this study. More than 60% of tumor cell areas were selected microscopically and isolated with microdissection. DNA was extracted with the proteinase K and sodium dodesyl sulfate (SDS) method (Goelz et al., 1985) . Tissues were incubated overnight at 528C in lytic solution. The tissue lysate was treated with phenolchloroform to extract the DNA.
Screening of allelic loss and microsatellite instability
For microsatellite analysis, 31 primer pairs were obtained from Research Genetics (Huntsville, AL). The following microsatellite loci were examined for MSI and LOH using two to ®ve markers on each respective chromosomal arm: 2p (D2S119, D2S123, D2S147, D2S378, and D2S391); 3p (D3S1611, D3S1619, D3S1209, and D3S1283); 5q (D5S107, D5S409, and IRF1); 9p (D9S171, IFNA, D9S162, and D9S165); 11p (D11S861 and D11S1392); 13q (D13S118, D13S133, D13S135, D13S170, and D13S120); 17p (TP53, D17S520, D17S513, D17S786, and D17S796); 18q (D18S34 and DCC). Genomic DNAs were ampli®ed with 1 mCi of [ 32 P]dCTP in 10 m1 reaction mixture by multiplex PCR. Thirty-two cycles of ampli®cation reaction were performed at 958C for 50 s, 568C to 608C for 90 s, and 728C for 90 s. Ampli®ed products were diluted 1/10 with a denaturing buer containing 95% formamide and denatured completely by heating. Samples were electrophoresed on 6% denaturing gel and visualized by autoradiography. For p53 LOH study using intragenic markers, three p53 polymorphic sequences were ampli®ed with the following primer sets; 5'-CACCCATCTACAGTCCCCCTTGC-3' and 5'-GTGTAGGAGCTGCTGGTG-3' for BstUI RFLP site within exon 4, 5'-AGGTCTGGTTTGCAACTGGG-3' and 5'-GAGGTCAAATAAGCAGCAGG-3' for MspI RFLP site within intron 6, and 5-AAGAGCTGA-GACTCCGTCTC-3' and 5'-ACAGCTCCTTTAATGG-CAGG-3' for VNTR sequence within intron 1. Except for the VNTR marker, PCR products were digested with appropriate restriction enzymes. The digested or nondigested PCR products were seen by electrophoresis on polyacrylamide gels followed by staining with ethidium bromide and photographing under u.v. light.
Detection of p53 mutations and TGF-b RII, BAX, IGFIIR, hMSH3 and hMSH6 frameshift mutations Mutations of p53 were analysed by direct PCR product sequencing. Exon 5-8 of the p53 were ampli®ed using the Human p53 Exon 4 ± 9 Ampli®er TM (Clontech) according to the manufacturer's instructions. Brie¯y, genomic DNA was ampli®ed in a volume of 15 ml reaction mixture. Of this volume, 5 ml was used to run on agarose gel for checking the quality and quantity of ampli®ed DNA. Roughly 30 ± 50 ng of product DNA in the remaining 10 ml was treated with 10 units of Exonuclease I and 2 units of Shrimp Alkaline Phosphatase. The treated PCR products were divided into two tubes and annealed with 10 pmol of the same up-and downstream primers as used in PCR. The sequencing procedure was performed by using the Sequenase PCR sequencing Kit TM (USB). To detect MSIassociated frameshift mutations in the coding regions, repetitive mononucleotide tracts of TGF-b RII, BAX, hMSH3, hMSH6 and IGFIIR were ampli®ed using the following primer sets; 5'-CTTTATTCTGGAAGATGCT-GC-3' and 5'-GAAGAAAGTCTCACCAGG-3' for the poly(A) 10 tract of TGF-b RII, 5'-ATCCAGGATCGAG-CAGGGCG-3' and 5'-ACTCGCTCAGCTTCTTGGTG-3' for the poly(G) 8 tract of BAX, 5'-AGATGTGAATCCCC-TAATCAAGC-3' and 5'-ACTCCCACAATGCCAATAA-AAAT-3' for the poly(A) 8 tract of hMSH3, 5'-GGGTGATGGTCCTATGTGTC-3' and 5'-CGTAATG-CAAGGATGGCGT-3' for the poly(C) 8 tract of hMSH6, and 5'-GCAGGTCTCCTGACTCAGAA-3' and 5'-GAA-GAAGATGGCTGTGGAGC-3' for the poly(G) 8 tract of the IGFIIR. Reaction condition consisted of 32 cycles at 948C for 1 min, 53 to 608C for 1 min, and 728C for 1 min using 1mCi of [ 32 P]dCTP into 10 ml reaction mixture. DNA denaturation, electrophoresis and autoradiography procedure were done likewise with MI/LOH study.
